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Validation of a Point-of-Care Quantitative Equine IgG
Turbidimetric Immunoassay and Comparison of IgG Concentrations
Measured with Radial Immunodiﬀusion and a Point-of-Care IgG
ELISA
S. Ujvari, C.C. Schwarzwald, N. Fouche, J. Howard, and A. Schoster
Background: Point-of-care (POC) diagnostic tests with good sensitivity and speciﬁcity are needed for diagnosing failure of
transfer of passive immunity (FTPI) in foals. Turbidimetric immunoassays (TIA) have these characteristics and provide quan-
titative results. A commercially available TIA-based POC test (POC-TIA) has not been validated in horses.
Objective: To validate a POC-TIA and compare results of POC-TIA, a POC-ELISA, and radial immunodiﬀusion (RID).
Animals: Heparinized blood samples (n = 127) from 48 hospitalized foals (<12 hour to 48 days).
Methods: Prospective validation study. IgG concentrations were measured using RID (gold standard), POC-TIA, and
POC-ELISA. Agreement between assays was assessed using Bland–Altman analysis. Sensitivity and speciﬁcity were calculated
using ROC curves. Inter- and intra-assay coeﬃcients of variation (CVs) and linearity were evaluated for POC-TIA.
Results: The mean bias (95% limits of agreement) between RID and POC-TIA was 4 (185 to 176), 27 (201 to 255),
and 308 (377 to 993) mg/dL for samples with IgG concentrations of <400, 400–800, and >800 mg/dL, respectively. Sensitiv-
ity and speciﬁcity at optimal cutoﬀ were 94 and 100% for the POC-TIA and 94 and 100% for the POC-ELISA to detect
IgG <400 mg/dL, and 85 and 87% (POC-TIA) and 69 and 79% (POC-ELISA) to detect IgG ≤800 mg/dL. Intra- and interas-
say CVs for POC-TIA ranged between 1.6–3.8 and 11.9–18.8%, respectively. Linearity of the dilution series was preserved
(R2 > 0.96).
Conclusions and Clinical Importance: The POC-TIA provided unambiguous results and had suﬃcient sensitivity, speci-
ﬁcity, accuracy, and precision to be used as an alternative to other POC tests to assess FTPI in foals.
Key words: Failure of transfer of passive immunity; Foal; Horse; Radial immunodiﬀusion.
Failure of transfer of passive immunity (FTPI) iscommon in neonatal foals and predisposes them to
severe infections.1,2 Early detection of FTPI is therefore
important to ensure adequate and timely treatment.1,3,4
Immunoglobulin G (IgG) concentrations of >800 mg/
dL measured 12–48 hour postnatum are generally con-
sidered adequate,2 and FTPI is commonly deﬁned as
partial FTPI at IgG concentrations of 400–800 mg/dL
or total FTPI at IgG concentrations <400 mg/dL.1,2
A variety of quantitative and semiquantitative meth-
ods have been used to determine IgG concentrations in
neonatal foals,5–7 but radial immunodiﬀusion (RID) is
considered the gold standard for the diagnosis of FTPI.
However, RID has a long turnaround time, requires
expertise in result interpretation, and is costly.3,8 Serum
electrophoresis has been suggested as an alternative
gold standard to RID and may be more accurate and
reliable in interpretation, but electrophoresis also
requires specialized laboratory equipment and has a rel-
atively long turnaround time.3,5,9,10
Several rapid, inexpensive point-of-care tests for clini-
cal use, including an ELISAa, zinc sulfate turbidity test,
glutaraldehyde coagulation tests, and latex agglutina-
tion tests, have been shown to have acceptable sensitiv-
ity and speciﬁcity.6,7,9,11 However, these tests provide
only semiquantitative results and are subject to interpre-
tation error. Estimates of IgG concentrations based on
serum total protein concentrations are considered
unreliable,1,5,6,12 and serum total globulins have limited
sensitivity and speciﬁcity.2,3,13
An automated turbidimetric immunoassay developed
for quantitative IgG measurements in horses has ade-
quate sensitivity and speciﬁcity, but testing requires a
laboratory chemistry analyzer and is not convenient for
From the Equine Department, Vetsuisse Faculty, University of
Zurich, Zurich, Switzerland (Ujvari, Schwarzwald, Schoster); the
Swiss Institute of Equine Medicine, ISME, Vetsuisse Faculty,
University of Bern and Agroscope, Bern, Switzerland (Fouche); and
the Clinical Diagnostic Laboratory, Vetsuisse Faculty, University of
Bern, Bern, Switzerland (Howard).
The work was performed at the University of Zurich and the
University of Bern.
Presented as a poster at the 2nd International Congress of the
German Equine Veterinary Association (GEVA), Berlin, October
28, 2016–October 29, 2016.
Corresponding author: Dr. A. Schoster, Winterthurerstrasse 260,
8057 Zurich, Switzerland; e-mail: aschoster@vetclinics.uzh.ch
Submitted February 22, 2017; Revised April 11, 2017;
Accepted April 27, 2017.
Copyright © 2017 The Authors. Journal of Veterinary Internal
Medicine published by Wiley Periodicals, Inc. on behalf of the Ameri-
can College of Veterinary Internal Medicine.
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original
work is properly cited and is not used for commercial purposes.
DOI: 10.1111/jvim.14770
Abbreviations:
AUC area under the curve
CV coeﬃcient of variation
FTPI failure of transfer of passive immunity
IgG immunoglobulin G
LR likelihood ratio
POC-ELISA point-of-care ELISA
POC-TIA point-of-care turbidimetric assay
RID radial immunodiﬀusion
ROC receiver operator characteristics
SD standard deviation
Standard Article
J Vet Intern Med 2017
use in daily practice.8 More recently, point-of-care ana-
lyzers that use the turbidimetric immunoassay technique
have been developed. One of these analyzers has good
sensitivity and speciﬁcity, but is no longer available.14
Another point-of-care turbidimetric analyzer (POC-
TIAb) is currently marketed, but there are thus far no
published validation studies.
The objective of this study was to validate the POC-
TIAb and compare the performance of the POC-TIAb
and of a widely used point-of-care ELISA (POC-
ELISAa) to the gold standard RID assay.
Materials and Methods
Animals
Foals presented to the Equine Hospitals of the Universities of
Zurich and Bern between February and July 2015 were included in
the study. Foals were included if testing for FTPI was considered
indicated by the attending clinicians. Multiple samples from the
same foal were included when IgG concentrations were measured
on multiple occasions throughout the course of treatment. The
study was performed in accordance with the animal use guidelines
of the Swiss legislation and approved by Cantonal Veterinary
oﬃces in Zurich and Bern. The “Standards for the Reporting of
Diagnostic Accuracy guidelines” were followed.15
Samples
Blood samples were obtained from the jugular vein by direct
venipuncture or from an indwelling intravenous catheter. 6 mL of
native blood and 3 mL of heparinized blood were collected from
each foal. Native blood was allowed to clot at room temperature
for 60 minutes before centrifugation at 1341 g for 11 minutes. The
serum was then transferred to cryotubes and frozen at 80°C.
Heparinized blood was centrifuged at 1341 g for 11 minutes at
room temperature, and plasma was used immediately to perform
POC-TIAb and POC-ELISA.a The remainder of the plasma was
transferred to a cryotube and frozen at 80°C.
Laboratory Analyses
The POC-TIAb and POC-ELISAa were run according to the
manufacturers’ recommendations on heparinized plasma and eval-
uated by an experienced clinician. Results from POC-ELISAa were
read before the results from POC-TIAb. Quality control of the
POC-TIAb analyzer was carried out as recommended by the man-
ufacturer throughout the study period. Linearity of the POC-TIAb
dilution series was determined by linear regression using 2 plasma
samples of high concentration measured undiluted and diluted
with phosphate-buﬀered saline at concentrations of 1:2, 1:4, 1:8,
and 1:16. Intra-assay variability of the POC-TIAb was assessed by
the coeﬃcient of variation of ten replicate measurements of each
of 3 samples, analyzed on the same setup of the assay. Interassay
variability of the POC-TIAb was assessed by the CV of 5 replicate
measurements of each of 3 samples (low, medium, and high con-
centration), analyzed on diﬀerent setups of the experiment. Coeﬃ-
cients of variation of <25% were considered acceptable.16 Samples
for intra-assay and interassay variability were randomly selected
based on low (<400 mg/dL), medium (400–800 mg/dL), and high
concentration (>800 mg/dL).
The frozen serum samples were shipped as a single batch on
dry ice to MAI P/S laboratory (Spring Valley, WI) for RID analy-
ses that were conducted with a commercial RID test kit.c The lab-
oratory personnel were blinded to the results of the POC-TIAb
and POC-ELISAa tests. Standard curves were performed on each
individual RID plate using the manufacturer’s suggested protocol
with serial dilutions of a commercial USDA certiﬁed Equine IgGd
prepared with sterile goat serum.e In addition to standards and
unknowns, all RID plates included 3 control samples (high,
1900 mg/dL; mid, 950 mg/dL; and low, 475 mg/dL), standards
supplied by the manufacturer of the RID plates and, on 3 plates,
interassay (between plates) and intra-assay (with-in the same plate)
replicates of 3 test samples chosen to represent high, mid, and low
levels of IgG. The same 3 laboratory technicians processed all
samples to reduce subjectivity. The average of the 3 reads was
reported as the result of RID. The same USDA approved stan-
dard was used for all RID plates to reduce variability.
Statistical Analyses
Descriptive statistics were used to summarize data. Agreement
of the POC-TIAb with RID assay was evaluated using Bland–Alt-
man analysis, whereby data were analyzed separately for samples
with RID IgG concentrations of <400, 400–800, and >800 mg/dL,
respectively. The mean bias, the 95% conﬁdence interval (CI) of
the mean bias, and the 95% limits of agreement (LOA) were cal-
culated. Samples were categorized based on RID as ≤800 mg/dL
(partial or total FTPI), and <400 mg/dL (total FTPI) to evaluate
the performance of the POC-TIAb and POC-ELISAa. Receiver
operator characteristics (ROC) were used to determine the accu-
racy of POC-TIAb. The area under the ROC curve (AUC) was
calculated, and the Youden index (=maximum {sensitivity + speci-
ﬁcity – 1}) was used to identify the optimal cutoﬀ points for both
sensitivity and speciﬁcity of the POC-TIAb to detect IgG concen-
trations <400 mg/dL (total FTPI) and ≤800 mg/dL (partial or
total FTPI), respectively. Other cutoﬀs were chosen to maximize
either speciﬁcity or sensitivity of the assay. Test characteristics at
the respective cutoﬀ values were summarized by reporting sensitiv-
ity, speciﬁcity, and positive (+LR) and negative (LR) likelihood
ratios. Similarly, the performance of the POC-ELISAa was evalu-
ated after generating ROC curves from the predicted probabilities
from logistic regression. In addition, classiﬁcation agreement of
samples with IgG >800 mg/dL, 400–800 mg/dL, and <400 mg/dL
between POC-TIAb and RID assay and between POC-ELISAa
and RID assay was evaluated using the Kappa statistic with linear
weights. The level of signiﬁcance was set at P < 0.05. Analyses
were performed by commercial software.f,g
Results
Animals
A total of 127 samples were collected from 48 foals
(87 samples from 20 foals presented to the Equine
Hospital of University of Zurich and 40 samples from
28 foals presented to the Equine Hospital of the
University of Bern). The sex of the foals was female in
18/48 (37.5%) and male in 30/48 (62.5%) of cases. The
age at sampling ranged from <12 hours to 38 days, with
a median of 4 days. Breeds included 19 Warmblood
horses, 10 Freiberger, 8 ponies, 2 donkeys, 2 draft
horses, 2 Lusitanos and one each of Standardbred,
Thoroughbred, Friesian, Quarter Horse, and Paso Fino.
Presenting complaints recorded were FTPI (7/48),
colic (7/48), sepsis (5/48), noninfectious orthopedic dis-
ease (5/48), healthy foals accompanying their sick mare
(5/48), omphalitis (3/48), pneumonia (3/48), weakness
(2/48), uroabdomen (2/48) and one each of prematurity,
white muscle disease, inguinal hernia, soft tissue
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trauma, wry nose, fever, and esophageal obstruction.
The presenting complaint was not recorded for 2/48
foals.
Samples
A single blood sample was collected from 29 foals.
Foals from which more than one sample was collected
were as follows: 2 samples (n = 7), 3 samples (n = 3), 4
samples (n = 1), 5 samples (n = 1), 6 samples (n = 2), 7
samples (n = 1), 9 samples (n = 1), eleven samples
(n = 1), thirteen samples (n = 1), and 14 samples
(n = 1). A total of 67/127 samples were taken after
plasma transfusion. Based on RID analyses, IgG con-
centrations were >800 mg/dL in 75/127 (59%) samples,
400–800 mg/dL (partial FTPI) in 36/127 (28%) samples,
and <400 mg/dL (total FTPI) in 16/127 (13%) samples.
Any FTPI (partial or total) was present in 52//127
(41%) of samples.
Evaluation of POC-TIAb
Linearity of the dilution series was preserved for the
POC-TIAb assay (Fig 1, Table 1). Intra-assay variabil-
ity was within acceptable limits with CVs between 1.6
and 3.8% (Table 2). Interassay variability was higher
(CVs between 11.9 and 18.8%) than intra-assay vari-
ability for all IgG concentrations (Table 2), but still
within acceptable limits.
Agreement between POC-TIAb and RID using the
Bland–Altman analyses revealed a mean bias of 4 mg/
dL (95% CI, 53 to 45), 27 mg/dL (95% CI, 13 to
66), and 308 mg/dL (95% CI, 515 to 239) for sam-
ples with RID IgG concentrations of <400, 400–800,
and >800, respectively (Fig 2). For samples with RID
IgG concentrations of >800 mg/dL, a proportional
error was evident with POC-TIAb showing a greater
tendency to underestimate IgG concentrations as mea-
sured by RID assay at higher concentrations (Fig 2).
The AUC of the ROC curves for the POC-TIA was
0.99 and 0.92 to detect IgG concentrations of <400 and
≤800 mg/dL, respectively, when compared to the RID
assay as the gold standard (Fig 3). The Youden index
for detecting RID IgG concentrations of <400 and
≤800 mg/dL was associated with POC-TIAb cutoﬀ con-
centrations of 299 and 687 mg/dL, respectively. Cutoﬀ
concentrations for detecting RID IgG concentrations
with highest sensitivity and speciﬁcity are given in
Tables 3 and 4.
Table 1. Analytic accuracy of POC-TIAb assessed by linear regression of dilution series in spiked plasma samples.
Sample
Starting concentration
(mg/dL)
Regression line
Slope (95% CI) Y-intercept (95% CI) P R2
P (deviation from
line of equality)
A 3,379 1.013 (0.74–1.28) 183.5 (649.7 to 282.8) 0.0012 0.97 1.000
B 2,906 0.9948 (0.706–1.283) 110.6 (543.6 to 322.5) 0.0016 0.96 1.000
CI, conﬁdence interval.
Fig 1. Regression lines (solid lines) and 95% conﬁdence intervals
(dashed lines) showing the relation between observed and expected
IgG concentrations measured using the point-of-care turbidimetric
assay (POC-TIA) assay obtained after dilution of 2 plasma sam-
ples (A and B) with high IgG concentrations.
Table 2. Intra- and interassay variability of the point-
of-care turbidimetric assay (POC-TIAb).
Evaluation Sample
Mean (SD)
concentration (mg/dL) CV (%)
Intra-assay
variability
High 2267 (86.5) 3.8
Medium 658.8 (10.6) 1.6
Low 361.3 (9.9) 2.7
Interassay
variability
High 1653 (285.1) 17.2
Medium 720 (135.4) 18.8
Low 515.6 (61.5) 11.9
CV, coeﬃcient of variation.
Low: <400 mg/dL, medium: 400–800 mg/dL, high concentration
>800 mg/dL.
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The weighted Kappa value characterizing agreement
between POC-TIAb and RID assay for the classiﬁcation
of samples as IgG <400, 400–800, and >800 mg/dL,
respectively, was 0.64 (95% CI, 0.53–0.75). Total FTPI
(<400 mg/dL) was falsely diagnosed by POC-TIAb in 5/
20 (25%) samples, and 1/16 (6%) samples with total
FTPI based on RID was missed by POC-TIAb; IgG
concentrations ≤800 mg/dL (partial or total FTPI) were
falsely diagnosed by POC-TIAb in 2/50 (4%) samples,
and 27/75 (36%) samples with IgG concentrations
≤800 mg/dL (partial or total FTPI) based on RID were
missed by POC-TIAb.
Evaluation of POC-ELISAa
Based on the POC-ELISAa results, 15/127 (12%) sam-
ples were classiﬁed as <400 mg/dL (total FTPI) and 52/
127 (41%) as ≤800 mg/dL (partial or total FTPI). The
AUC of the ROC curves for the POC-ELISA was 0.97
and 0.74 to detect IgG concentrations of <400 mg/dL (to-
tal FTPI) and ≤800 mg/dL (partial or total FTPI),
Fig 3. Receiver operator characteristic curves for the point-of-
care turbidimetric assay (POC-TIA) to detect IgG concentrations
of <400 mg/dL (A) and ≤800 mg/dL (B) measured with radial
immunodiﬀusion.
Fig 2. Bland–Altman plots showing agreement of the point-of-
care turbidimetric assay (POC-TIA) with radial immunodiﬀusion
(RID) for IgG concentrations in samples with RID concentrations
<400 mg/dL (A), 400–800 mg/dL, (B) and >800 mg/dL (C). The
solid line represents the mean bias; the 2 dashed lines represent the
95% limits of agreement, and the dotted line is the line of equal-
ity. The numbers in brackets represent the 95% CI of the mean.
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respectively, when compared to the RID as the gold stan-
dard (Fig 4). Sensitivity, speciﬁcity, and associated likeli-
hood ratios to detect FTPI based on IgG concentrations
<400 mg/dL (total FTPI) and ≤800 mg/dL (partial or
total FTPI), respectively, are presented in Tables 3 and 4.
The Kappa value characterizing agreement between
POC-ELISAa and RID for the classiﬁcation of samples
as IgG <400, 400–800, and >800 mg/dL was 0.63 (95%
CI, 0.50–0.76). No samples were falsely diagnosed as
total FTPI by POC-ELISAa, and 1/16 (6%) samples with
total FTPI based on RID was missed by POC-ELISAa;
IgG concentrations ≤800 mg/dL (partial or total FTPI)
were falsely diagnosed by POC-ELISA in 16/52 (31%)
samples, and 16/52 (31%) samples with IgG concentra-
tions ≤800 mg/dL (partial or total FTPI) based on RID
were missed by POC-ELISA.a
Discussion
A quantitative point-of-care test oﬀers a great
advantage compared to most currently available assays
marketed for the assessment of FTPI in foals that give
only semiquantitative results. In particular, semiquanti-
tative tests giving a result between 400 and 800 mg/dL
do not allow clinicians to distinguish animals with IgG
concentrations bordering on total FTPI from those
with concentrations close to adequate levels. Moreover,
the eﬀects of treatment cannot be as closely monitored
by semiquantitative tests. The purpose of this study
was to validate a quantitative POC-TIAb and compare
IgG concentrations measured with RID and both the
POC-TIAb and a widely used semiquantitative POC-
ELISAa. The POC-TIAb showed both good linearity
in dilution series and good precision, based on intra-
and interassay CV. The test showed fair to good
agreement with the gold standard RID and had better
sensitivity and speciﬁcity than the POC-ELISAa in this
study.
The POC-TIAb evaluated in this study showed good
linearity in dilution series. Intra-assay variability (CVs,
1.6–3.8%) was similar to that reported in a previous
study (CV, 3%) evaluating an automated TIA per-
formed on a routine laboratory chemistry analyzer.8
Interassay variability (CVs, 11.9–18.8%) was consider-
ably higher than that reported using an automated TIA
(CVs, 1–4%).8 However, the range of values measured
for interassay CVs in the current study was greater than
that evaluated in the previous study. Moreover, both
intra- and interassay CVs were well within acceptable
limits of 25%.16,17 Several factors can inﬂuence the ana-
lytic performance of an assay. Small diﬀerences in sam-
ple handling and test setup can lead to variations. The
more steps included in a protocol, the higher the chance
for variation.17–19 This explains the slightly better coeﬃ-
cient of variation in the intra-assay experiment where
measurements were carried out repeatedly compared to
the interassay experiment, where the actual setup was
repeated. The good analytic performance of the POC-
TIAb suggests that small diﬀerences in manipulation are
not likely to lead to clinically relevant error in IgG
measurement, and precise measurements of IgG at clini-
cally relevant concentrations are possible.
Table 3. Sensitivities, speciﬁcities, and likelihood ratios of a point-of-care turbidimetric assay (POC-TIAb) and
point-of-care ELISA (POC-ELISAa) to detect IgG concentrations <400 mg/dL (total FTPI, n = 16/127) as deter-
mined by the RID assay as the gold standard).
Assay AUC (95% CI)
Associated
cutoﬀ (mg/dL)
Sensitivity
(95% CI) Speciﬁcity (95% CI) +LR (95% CI) LR (95% CI)
POC-TIAb 0.99 (0.96–1.00) ≤299* 93.8 (69.8–99.8) 100.0 (96.7–100.0) 0.06 (0.01–0.40)
≤399 93.8 (69.8–99.8) 95.5 (89.8–98.5) 20.81 (8.8–48.5) 0.07 (0.01–0.40)
≤488 100.0 (79.4–100.0) 90.1 (83.0–94.9) 10.09 (5.8–17.7)
POC-ELISAa 0.97 (0.92–0.99) ≤400 93.8 (69.8–99.8) 100 (96.7–100.0) 0.06 (0.01–0.42)
AUC, area under the curve of ROC curve analysis; CI, conﬁdence intervals; LR, likelihood ratio; RID, radial immunodiﬀusion; FTPI,
failure of transfer of passive immunity.
*Optimal cutoﬀ as determined by the Youden index.
Table 4. Sensitivities, speciﬁcities, and likelihood ratios of a point-of-care turbidimetric assay (POC-TIAb) and
point-of-care ELISA (POC-ELISAa) to detect RID IgG concentrations ≤800 mg/dL (partial or total FTPI, n = 52/
127) as determined by the RID assay as the gold standard).
Assay AUC (95% CI)
Associated
cutoﬀ (mg/dL) Sensitivity (95% CI) Speciﬁcity (95% CI) +LR (95% CI) LR (95% CI)
POC-TIAb 0.92 (0.86–0.96) ≤391 36.4 (23.6–51) 100 (95.2–100) 0.63 (0.5–0.8)
≤595 69.2 (54.9–81.3) 96 (88.8–99.2) 17.31 (5.6–53.2) 0.32 (0.2–0.5)
≤687* 84.6 (71.9–93.1) 86.7 (76.8–93.4) 6.35 (3.5–11.4) 0.18 (0.1–0.3)
≤804 98.1 (89.7–100.0) 62.7 (50.7–73.6) 2.63 (2.0–3.5) 0.03 (0.00–0.20)
≤864 100 (93.2–100) 49.3 (37.6–61.1) 1.97 (1.6–2.5)
POC-ELISAa 0.74 (0.65–0.81) ≤800 69.2 (54.9–81.3) 78.7 (67.7–87.3) 3.25 (2.0–5.2) 0.39 (0.26–0.60)
AUC, area under the curve of ROC curve analysis; CI, conﬁdence intervals; LR, likelihood ratio; RID, radial immunodiﬀusion; FTPI,
failure of transfer of passive immunity.
*Optimal cutoﬀ as determined by the Youden index.
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Agreement between POC-TIAb and the gold standard
RID was good for samples with RID IgG concentrations
of <400 and 400–800 mg/dL. For samples with RID IgG
concentrations of >800 mg/dL, both considerable bias
and proportional error were evident with the POC-TIAb,
measuring increasingly lower than RID assay with
increasing IgG concentrations. However, as IgG concen-
trations above 800 mg/dL are considered to be adequate
to protect foals against infections, this increasing bias is
likely to be of little clinical importance.
A test with high sensitivity is desirable when assessing
FTPI, as failure to diagnose (and treat) FTPI may have
serious sequela.14,20,21 Conversely, high speciﬁcity is nec-
essary to avert unnecessary treatment of foals with
plasma transfusions, which carries a risk of adverse
eﬀects and is associated with higher costs.22 The AUC
of ROC curve analyses for POC-TIAb to detect RID
IgG concentrations <400 mg/dL (total FTPI) and
≤800 mg/dL (partial or total FTPI) was both very high
and considerably higher than that of POC-ELISAa.
Moreover, optimal cutoﬀ points based on the Youden
index (i.e, 299 and 687 mg/dL) achieved a sensitivity
and speciﬁcity similar or superior to those found with
the POC-ELISAa, and those previously reported using a
diﬀerent POC-TIA assay (80 and 100%, respectively)14
and an automated TIA (63 and 92%, respectively).8
Likewise, optimal cutoﬀ points achieved sensitivities
and speciﬁcities similar or superior to those of the
POC-ELISAa, and those previously reported using a
diﬀerent POC-TIA assay (76 and 100%, respectively)14
and using an automated TIA (81 and 86%,
respectively).8 Although cutoﬀ values determined by the
Youden index resulted in some foals with FTPI being
missed by POC-TIAb, this can be averted by selecting
higher cutoﬀ values of 488 and 804 mg/dL to detect
IgG concentrations <400 (total FTPI) and ≤800 mg/dL
(total or partial FTPI, as measured by RID), respec-
tively. These higher cutoﬀ values result in sensitivities
of 100 and 98.1%, respectively, decreasing the false-
negative rate at the expense of lower speciﬁcities.
Results of the present study therefore suggest that the
POC-TIAb provides suﬃcient diagnostic accuracy to
assess FTPI in foals.
Although the overall Kappa agreement to classify
samples as <400, 400–800, and >800 mg/dL was similar
for the POC-TIAb and POC-ELISAa, results of ROC
curve analyses suggest that POC-TIAb is superior to
POC-ELISAa. However, as the POC-TIAb measured
lower than RID, assay-speciﬁc cutoﬀs are necessary to
achieve optimal performance. Indeed, use of 400 and
800 mg/dL as cutoﬀs for the POC-TIAb would result in
lower speciﬁcities than those achieved with Youden
index-based cutoﬀs.
Previous studies evaluating the POC-ELISAa have
reported sensitivities and speciﬁcities ranging of 89–90
and 79–96%, respectively, to detect RID <400 mg/dL,
and 81–95 and 52–95%, respectively to detect RID
≤800 mg/dL.6,12 However, diﬀerences in prevalences of
FTPI between studies and use of diﬀerent RID assays
make direct comparison with other studies diﬃcult.
Multiple samples from foals were included in the
study as samples were used to monitor the foal IgG
concentrations over time after plasma transfusion.
These samples were not considered repeated measures,
as most of them received plasma for treatment of FTPI
between sampling points.
As evaluation of the POC-ELISAa is somewhat sub-
jective and both the POC-TIAb and POC-ELISAa were
run by the same operator at the same time, results of
the POC-ELISAa were read before performing the
POC-TIAb. Therefore, results of POC-TIAb should not
have inﬂuenced subjective reading of the POC-ELISAa.
The POC-TIAb can be performed with both serum and
Fig 4. Receiver operator characteristic (ROC) curves for the
point-of-care ELISA (POC-ELISA) to detect IgG concentrations
of <400 mg/dL (A) and ≤800 mg/dL (B) measured with radial
immunodiﬀusion. ROC curves for were calculated from the pre-
dicted probabilities from logistic regression.
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plasma. In this study, plasma was used for convenience
although serum was used for RID assays. However, as
a previous study showed no diﬀerence in IgG concen-
trations between serum and plasma using an automated
TIA assay, no signiﬁcant eﬀect of matrix is expected.21
From a practical standpoint, the POC-TIAb was
found to be easy to perform, rapid (run time of approx-
imately 15 minutes) and the measured concentrations
are displayed digitally, giving unambiguous results that
are not subject to individual interpretation bias.
In conclusion, the POC-TIAb showed fair to good
overall performance and its use in practice can be con-
sidered as an alternative to other point-of-care tests for
the diagnosis of FTPI in foals. Assay-speciﬁc cutoﬀs are
necessary to achieve optimal accuracy compared to
RID.
Footnotes
a SNAP Foal IgG Test Kit, IDEXX Laboratories Inc, Westbrook,
ME
b Rapid DVM testTM II, Value DiagnosticsTM, MAI Animal Health,
Melksham, Wiltshire, UK
c RID Test for Equine IgG, product number 828411, Triple J
Farms, Bellingham, WA
d Secondary Reference Serum (SRS), Product Number 2011, Mid-
land BioProducts, Boone, IA
e Equitech-Bio, Kerrville, TX
f MedCalc, version 16.4.1 MedCalc Software bvba, Ostend,
Belgium
g GraphPad Prism, version 5.03, GraphPad Software, San Diego,
CA, USA, www.graphpad.com
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